Wen Chyi Shyu
Biotechnology
BRIM Biotech
Taiwan
Biography
Wen Chyi has extensive background and experience in pharmaceutical research as a scientist, manager and leader. She has a total of more than 30 years of industrial experience in drug metabolism and pharmacokinetic aspects of drug discovery, development and life cycle management. She has made contributions to the development of brand-name drugs such as cefprozil, cefepime, transnasal butorphanol, videx, bvaraU, irbesartan, irbesartan/HTCZ, pravastatin, dasatinib, ixabepilone, muraglitazar, abatacept, saxagliptin, dapagloflozin, Brentuximab vedotin and vedolizumab. She was also responsible for more than 100 IND submissions. She is currently the VP of Global Drug Metabolism and Pharmacokinetics in Takeda. Before joined Takeda in 2010, Wen Chyi has worked for Bristol-Myers Squibb for 24 years.
Research Interest
Pharmaceutical Sciences